These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 24816562)
1. Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors. Nie P; Li D; Hu L; Jin S; Yu Y; Cai Z; Shao Q; Shen J; Yi J; Xiao H; Shen L; He B PLoS One; 2014; 9(5):e97009. PubMed ID: 24816562 [TBL] [Abstract][Full Text] [Related]
2. Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. Bot I; Jukema JW; Lankhuizen IM; van Berkel TJ; Biessen EA Atherosclerosis; 2011 Feb; 214(2):295-300. PubMed ID: 21130458 [TBL] [Abstract][Full Text] [Related]
3. In vivo fluorescence-mediated tomography imaging demonstrates atorvastatin-mediated reduction of lesion macrophages in ApoE-/- mice. Larmann J; Frenzel T; Schmitz M; Hahnenkamp A; Demmer P; Immenschuh S; Tietge UJ; Bremer C; Theilmeier G Anesthesiology; 2013 Jul; 119(1):129-41. PubMed ID: 23559030 [TBL] [Abstract][Full Text] [Related]
4. The complementary effects of atorvastatin and exercise treatment on the composition and stability of the atherosclerotic plaques in ApoE knockout mice. Moustardas P; Kadoglou NP; Katsimpoulas M; Kapelouzou A; Kostomitsopoulos N; Karayannacos PE; Kostakis A; Liapis CD PLoS One; 2014; 9(9):e108240. PubMed ID: 25264981 [TBL] [Abstract][Full Text] [Related]
5. Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E-knockout mice. Li G; Wu XW; Lu WH; Ai R; Chen F; Tang ZZ BMC Cardiovasc Disord; 2014 Oct; 14():145. PubMed ID: 25326709 [TBL] [Abstract][Full Text] [Related]
6. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice. Yang LX; Heng XH; Guo RW; Si YK; Qi F; Zhou XB J Cardiovasc Pharmacol; 2013 Aug; 62(2):205-11. PubMed ID: 23615158 [TBL] [Abstract][Full Text] [Related]
7. Atorvastatin attenuates atherosclerotic plaque destabilization by inhibiting endoplasmic reticulum stress in hyperhomocysteinemic mice. Jia F; Wu C; Chen Z; Lu G; Sun J Mol Med Rep; 2016 Apr; 13(4):3574-80. PubMed ID: 26956896 [TBL] [Abstract][Full Text] [Related]
8. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605 [TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Katsuki S; Matoba T; Nakashiro S; Sato K; Koga J; Nakano K; Nakano Y; Egusa S; Sunagawa K; Egashira K Circulation; 2014 Feb; 129(8):896-906. PubMed ID: 24305567 [TBL] [Abstract][Full Text] [Related]
10. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. Waehre T; Damås JK; Gullestad L; Holm AM; Pedersen TR; Arnesen KE; Torsvik H; Frøland SS; Semb AG; Aukrust P J Am Coll Cardiol; 2003 May; 41(9):1460-7. PubMed ID: 12742282 [TBL] [Abstract][Full Text] [Related]
11. MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis. Nachtigal P; Pospisilova N; Pospechova K; Jamborova G; Kopecky M; Jaynes R; Briestensky J; Santar I; Smahelova A; Solichova D; Zdansky P; Semecky V Life Sci; 2006 Mar; 78(17):1983-9. PubMed ID: 16305803 [TBL] [Abstract][Full Text] [Related]
12. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Schober A; Zernecke A; Liehn EA; von Hundelshausen P; Knarren S; Kuziel WA; Weber C Circ Res; 2004 Nov; 95(11):1125-33. PubMed ID: 15528472 [TBL] [Abstract][Full Text] [Related]
13. Atorvastatin suppresses inflammatory response induced by oxLDL through inhibition of ERK phosphorylation, IκBα degradation, and COX-2 expression in murine macrophages. Shao Q; Shen LH; Hu LH; Pu J; Jing Q; He B J Cell Biochem; 2012 Feb; 113(2):611-8. PubMed ID: 21956776 [TBL] [Abstract][Full Text] [Related]
14. Deficiency in lymphotoxin β receptor protects from atherosclerosis in apoE-deficient mice. Grandoch M; Feldmann K; Göthert JR; Dick LS; Homann S; Klatt C; Bayer JK; Waldheim JN; Rabausch B; Nagy N; Oberhuber A; Deenen R; Köhrer K; Lehr S; Homey B; Pfeffer K; Fischer JW Circ Res; 2015 Apr; 116(8):e57-68. PubMed ID: 25740843 [TBL] [Abstract][Full Text] [Related]
15. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. Bustos C; Hernández-Presa MA; Ortego M; Tuñón J; Ortega L; Pérez F; Díaz C; Hernández G; Egido J J Am Coll Cardiol; 1998 Dec; 32(7):2057-64. PubMed ID: 9857893 [TBL] [Abstract][Full Text] [Related]
16. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Xu ZM; Zhao SP; Li QZ; Nie S; Zhou HN Clin Chim Acta; 2003 Dec; 338(1-2):17-24. PubMed ID: 14637261 [TBL] [Abstract][Full Text] [Related]
17. Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture. Roth L; Rombouts M; Schrijvers DM; Martinet W; De Meyer GR Vascul Pharmacol; 2016 May; 80():50-8. PubMed ID: 26826559 [TBL] [Abstract][Full Text] [Related]
18. Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Rathouska J; Vecerova L; Strasky Z; Slanarova M; Brcakova E; Mullerova Z; Andrys C; Micuda S; Nachtigal P Pharmacol Res; 2011 Jul; 64(1):53-9. PubMed ID: 21440631 [TBL] [Abstract][Full Text] [Related]
19. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207 [TBL] [Abstract][Full Text] [Related]
20. Combination of tanshinone IIA and astragaloside IV attenuate atherosclerotic plaque vulnerability in ApoE(-/-) mice by activating PI3K/AKT signaling and suppressing TRL4/NF-κB signaling. Wang N; Zhang X; Ma Z; Niu J; Ma S; Wenjie W; Chen J Biomed Pharmacother; 2020 Mar; 123():109729. PubMed ID: 31887543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]